The Global Vitiligo Drugs Market Continues To Grow Owing To the Increasing Incidence of Vitiligo Cases in the World
Vitiligo Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and Psoralens), by Type (Segmental and Non-segmental), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 20.
Market Overview:
Vitiligo is an autoimmune condition that causes patches of skin to turn white or lighter than their natural color. It is a common skin disorder that can affect anyone, but it is especially noticeable in people with dark or tanned skin. The most common symptom of vitiligo is the appearance of flat, white spots or patches on the skin that gradually lose pigment and become lighter over time. These patches or spots are also called macules. They may be present in a single area or spread from other areas of the body. There is no cure for vitiligo, but treatment can help reduce the visibility of these patches and even out your skin tone. The best way to treat vitiligo is to work with the health care provider to choose the treatment.
According to Coherent Market Insights the Vitiligo Drugs Market Size, Share, Outlook, and Opportunity Analysis 2018 – 2026.
Competitive Landscape:
Major players operating in the global vitiligo drugs market include Temprian Therapeutics Inc., Arrien Pharmaceuticals LLC, Villaris Therapeutics, Arcutis Biotherapeutics, Inc., Applied Biology, Inc., Boston Pharmaceuticals, Clinuvel Pharmaceuticals Ltd., Bristol - Myers Squibb, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Aclaris Therapeutics, Inc., Incyte Corporation, and Dermavant Sciences, Inc.
Key Market Drivers:
The increasing prevalence of vitiligo in the world is expected to augment the growth of the global vitiligo drugs market. For instance, according to the Global Vitiligo Foundation, 70 million individuals in the world have vitiligo. If individuals have a lot of macules or large patches of vitiligo, the doctor might suggest treating the affected areas with a drug, surgery, or therapy that helps restore some of the skin's normal pigment. These treatments can be very effective and sometimes have a long-term effect on the condition. Some doctors prescribe a special medicine that is used on the skin and has been approved by the FDA for adults and children 12 and older with nonsegmental vitiligo. Moreover, increasing advancements in the dermatology sector worldwide are estimated to enhance the growth of the global vitiligo drugs market.
Covid-19 Impact Analysis
During the COVID-19 pandemic, the global vitiligo drugs market has witnessed several difficulties. The increasing burden of the healthcare sector along with the pharmaceutical sector has affected the market growth significantly. Transport restrictions and lockdown measures also impacted the growth of the market.
Key Takeaways
North America is expected to dominate the growth of the global vitiligo drugs market, owing to the increasing incidence of vitiligo cases in the region. For instance, according to Verywell Health, vitiligo affects around 2.8 million individuals in the U.S.
The Asia Pacific is estimated to witness high growth in the global vitiligo drugs market, owing to the increasing expansion of the dermatology sector in the region. For instance, according to The Japanese Dermatological Association, in Japan, the total number of hospitals with dermatology departments in 2021, was around 3,046.

Comments
Post a Comment